mainzbiomed.com (MYNZ): חוב כולל של החברה

Mainz Biomed N.V. (MYNZ) generates revenue by implementing ColoAlert DNA tests for the detection of colorectal tumors in Europe, offering a non-invasive alternative to colonoscopies. Scaling sales across B2B and B2C segments provides current income, while awaiting FDA approval remains a long-term objective. This price chart for Mainz Biomed N.V. (MYNZ) reflects a debt load of 0.00, with business success relying on physician recognition of these methods and their inclusion in government programs.

This indicator aggregates all short-term and long-term borrowings, allowing for an assessment of credit pressure and capital structure stability. By analyzing the debt load chart, an investor can forecast the default risk of Mainz Biomed N.V. (MYNZ), whose aggressive spending on the implementation of diagnostic systems amid negative cash flow makes the company critically dependent on external financing.